Home  »  Equity Investing   »  Caladrius Biosciences, Inc. (CLBS) Stock Declining...

Caladrius Biosciences, Inc. (CLBS) Stock Declining in Premarket, Here’s What you Should Know.

Caladrius Biosciences, Inc. (CLBS) is a leading biotherapeutic company developing treatment modes for the regeneration of damaged or wounded tissues. Some of the lead product candidates of the company include XOWNA or CLBS16 which is in Phase 2a study for the therapeutic potential against coronary microvascular dysfunction. HONEDRA is in Phase 2 clinical trials for the treatment of critical limb ischemia. CLBS201 is a cell therapy for treating chronic kidney diseases. OLOGO is used in the treatment of no-option refractory disabling angina.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


The price of CLBS stock during the regular trading on January 5, 2022, was $1.01 with a slight decline of 1.94%. At last check in the premarket on January 6, 2022, the stock was further significantly down by 4.11%.

CLBS: Events and Happenings

On January 04, 2022, CLBS reported that the company’s executive management presented at two investor conferences. the conferences include Virtual Biotech Showcase held from January 10–12 to January 17–19, 2022 and H.C. Wainwright BioConnect Conference held from January 10-13, 2022.

CLBS: Key Financials

On November 04, 2021, CLBS reported its financial results for the three months ended September 30, 2021. Some of the key updates are as follows.

Net Loss per Share

Basic and diluted net loss for third-quarter 2021 was $6.9 million or $0.12 per share as compared to the same period of 2020 when it was $5.3 million or $0.29 per share. The net loss increased over the year.

Total Assets

The total assets of the company for Q3 2021 were $102 million as compared to the same period of 2020 when the assets were $42 million.

CLBS: CEO Comments

Speaking at the occasion, CEO of CLBS David J. Mazzo said that the company optimized its developmental programs during the third quarter of 2021 despite the COVID-19 pandemic challenges. He further added that the current financial figures enabled CLBS to refine and execute the developmental goals along with assessing the strategic development prospects.

On October 04, 2021, CLBS reported that the company’s Executives presented at the following conferences Virtual UK Kidney Week Conference on October 4-7, Advanced Therapies Congress & Expo on October 5-6, Dawson James Securities Small Cap Growth Conference on October 20-21 and The LD Micro Main Event on October 12-14, 2021.

On September 08, 2021, CLBS reported that the company’s Executives presented at the H.C. Wainwright 23rd Annual Global Investment Conference held on September 13-15, 2021.


Although CLBS stock is 13% up the last month, and the company’s announcement of participation in the investor conferences, the current premarket stock of the company is on a declining verge possibly due to an uncertain market atmosphere. Analysts are proposing that the company should make solid investor-oriented strategies to gain momentum in the market.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts